Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent

Cerebral Arteriovenous Malformations Clinical Trial

Official title: Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent

Status Completed

Clinical Trial Summary

A non-interventional multicentric study for patients with a cerebral AVM for which endovascular treatment is indicated.

Clinical Trial Description

This observational study will collect data about the treatment of ruptured, unruptured, untreated or endovascular previously treated AVM's.

Primary endpoint is safety. Safety will be assessed with the number of procedure-related complications occurring during the endovascular treatment until 30 days after the final embolization.

Secondary endpoint is efficacy. Efficacy will be assessed by angiography and clinical outcome assessments (mRS).

For each patient enrolled, data will be collected at inclusion, at each embolization session and at 6 ± 1 months after the end of the endovascular treatment phase. ;

Related Conditions & MeSH terms

• Arteriovenous Malformations
• Cerebral Arteriovenous Malformations
• Congenital Abnormalities
• Hemangioma
• Intracranial Arteriovenous Malformations

• NCT number: NCT02602990
• Study type: Observational [Patient Registry]
• Source: Emboflu
• Status: Completed
• Start date: August 2015
• Completion date: May 2019